Çocukluk Çağında Multipl Skleroz

Hafler DA, Slavik JM, Anderson DE, O’Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunological Reviews 2005;204:208-31.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New England Journal of Medicine 2000;343:938-52.

Brola W, Steinborn B. Pediatric multiple sclerosis- currentstatus of epidemiology, diagnosis and treatment. Neurol Neurochir Pol. 2020;54(6):508- 17.

Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18(1):27.

Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59:1006.

Bigi S, Banwell B. Pediatric multiple sclerosis. J Child Neurol 2012; 27:1378.

Yılmaz Ü, Anlar B, Gücüyener K; Turkish Pediatric Multiple Sclerosis Study Group. Characteristics of pediatric multiple sclerosis: The Turkish pediatric multiple sclerosis database. Eur J Paediatr Neurol. 2017;21(6):864-72.

Nielsen NM, Westergaard T, Rostgaard K, Frisch M, Hjalgrim H, Wohlfahrt J, Koch-Henriksen N, Melbye M. Familial risk of multiple sclerosis: A nation wide cohort study. American Journal of Epidemiology 2005162:7 74- 8

Wu GF, Alvarez E. The immunopathophysiology of multiple sclerosis. Neurologic Clinics 2011; 29: 257-78.

Sospedra M, Martin R. Immunology of multiple sclerosis. Annual Review of Immunology 2005; 23: 683-747

Frohman EM, Racke MK, Raine CS. Multiple sclerosis the plaque and its pathogenesis. New England Journal of Medicine 2006;3 54: 942-55

Oksenberg JR, Hauser SL. Genetics of multiple sclerosis. NeurolClin 2005; 23:61.

Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurren cerates in multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100:12877.

Banwell BL. Pediatric multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4:245.

Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 2009; 22:219.

Banwell B, Krupp L, Kennedy J,Tellier R, Tenembaum S, Ness J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6:773.

Ascherio A, Munch M. Epstein-Barrvirusand multiple sclerosis. Epidemiology 2000; 11:220.

Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virüs associated with multiple sclerosis. Science. 2022;375(6578):296-301. doi: 10.1126/science.abj8222.

Bray PF, Luka J, Bray PF, Culp W, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptid esequence identities between EBNA and myelinbasic protein. Neurology 1992; 42:1798.

Van Amerongen BM, Dijkstra CD, Lips P, Polman CH. Multiple sclerosisand vitamin D: an update. Eur J ClinNutr 2004; 58:1095.

Hayes CE. Vitamin D: A natural inhibitor of multiple sclerosis. Proceedings of the Nutrition Society 2000; 59: 531-5

Nielsen NM, Munger KL, Koch-Henriksen N,Hougaard DM, Magyari M, Jorgensen KT, et al. Neonatal vitamin D statusand risk of multiple sclerosis: A population-basedcase-controlstudy. Neurology 2017; 88:44.

Mowry EM, Krupp LB, Milazzo M,Chabas D, Strober JB, Belman AL, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010; 67:618.

Langer-Gould A, Qian L, Tartof SY, Brara SM, Jacobsen SJ, Beaber BE, et al. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014;71(12):1506-13. doi: 10.1001/jamaneurol.2014.2633

Montgomery S, Hiyoshi A, Burkill S,Alfredsson L, Bahmanyar S, Olsson T. Concussion in adolescenceand risk of multiple sclerosis. Ann Neurol 2017; 82:554.

Munger KL, Bentzen J, Laursen B, Stenager E, Koch-Henriksen N, Sørensen TI, et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. MultScler. 2013;19(10):1323-9.

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, life style and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25-36.

Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al; Adult Neurology Departments KIDMUS Study Group. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603-13.

Belman AL, Krupp LB, Olsen CS, Rose JW, Aaen G, Benson L, et al. Characteristics of Children and Adolescents With Multiple Sclerosis. Pediatrics 2016; 138.

Gusev E, Boiko A, Bikova O, Maslova O, Guseva M, Boiko S, et al. The natural history of early onset multiple sclerosis: comparison of data from Moscowand Vancouver. Clin Neurol Neurosurg 2002; 104:203.

Simone IL, Carrara D, Tortorella C,Liguori M, Lepore M, Pellegrini F, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002; 59:1922.

Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New England Journal of Medicine 2000; 343: 938-52.

Dobson R, Giovannoni G. Multiple Sclerosis- a review. Eur J Neurol. 2019;26(1):27-40.

Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM; Italian Society of Paediatric Neurology Study Group on Childhood Multiple Sclerosis. Multiple sclerosis in children under 10 years of age. Neurol Sci. 2004; 25 Suppl4: S326- 35.

Kurtzke JF. Multiple sclerosis in time andspace—geographic clues to cause. J Neurovirol. 2000;6 Suppl2:S134-40.

Cameron MH, Nilsagard Y, Balance, gait, andfalls in multiple sclerosis. Handb Clin Neurol. 2018;159:237-50. doi: 10.1016/B978-0-444-63916-5.00015-X.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52. doi: 10.1212/wnl.33.11.1444. 61. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-73.

Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. MultScler 2013; 19:1261.

Efendi H, Ünal A, Mavioğlu H, Altunrende B, İçen NK, Ergün U ve ark. Efendi H, Kuşcu DY, editörler. Multipl Skleroz Tani ve Tedavi Kılavuzu. İstanbul: Galenos Yayınevi; 2018. p.9-122.

Arneth B, Kraus J. Laboratory biomarkers of Multiple Sclerosis (MS). Clin Biochem. 2022;99:1-8. doi: 10.1016/j.clinbiochem.2021.10.004.

Callen DJ, Shroff MM, Branson HM, Lotze T, Li DK, Stephens D, et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology. 2009;72(11):961- 7.

Samur BM, Pashayev A, Canpolat M. Çocukluk çağinda multipl skleroz. Canpolat M, editör. Nöroimmünoloji. 1. Baskı. Ankara: Türkiye Klinikleri; 2023. p.43-73.

Sacco S,Virupakshaiah A, Papinutto N, Schoeps VA, Akula A, Zhao H, Susceptibility-based imaging aid saccurate distinction of pediatric-onset MS from myelin oligodendrocyteglyco protein antibody-associated disease MultScler. 2023 Dec; 29(14): 1736–1747.

Ontaneda D, Cohen JA, Sati P. Incorporating the central vein signinto the diagnostic criteria for multiple sclerosis. JAMA Neurol 2023; 80: 657–658.

Meaton I, Altokhis A, Allen CM, Clarke M, Sinnecker ND, Giorgio A, et al. Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis. Mult Scler 2022; 28(14): 2212–2220.

Hemond CC, Reich DS, Dundamadappa SK. Paramagnetic rim lesions in multiple sclerosis: Comparison of visualization at 1.5-T and 3-T MRI. AJR Am J Roentgenol 2022; 219(1): 120–131.

Blindenbacher N, Brunner E,Asseyer S, Scheel M, Siebert N, Rasche L, et al Evaluation of the ‘ring sign’ andthe ‘coresign’ as a magnetic resonance imaging marker of disease activity and progression in clinically isolated syndrome and early multiple sclerosis. MultScler J ExpTranslClin. 2020 Jan-Mar; 6(1): 2055217320915480

Mehta V, Pei W, Yang G,Li S, Swamy E, Boster A, et al. Iron is a sensitive biomarker for inflammation in multiple sclerosislesions. PLoS ONE 2013; 8: e57573.

Montalban X. 2024 Revisions of the McDonald Criteria. Presented at ECTRIMS Congress; September 18-20, 2024; Copenhagen, Denmark. ScientificSession 1: New diagnosticcriteria.

Cortese I, Calabresi PA. Inflammatory and demyelinating disorders. In: Irani DN, ed. Cerebrospinal Fluid in Clinical Practice. 1st ed. Philadelphia, PA: Saunders; 2009.

Kiiski HS, NíRiada S, Lalor EC, Gonçalves NR, Nolan H, Whelan R, et al. Delayed P100-like latencies in multiple sclerosis: a preliminary investigationusing visuale voked spread spectrum analysis. PLoSOne. 2016;11(1):e0146084.

Waldman AT, Gorman MP, Rensel MR, Austin TE, Hertz DP, Kuntz N, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United Statesneurologists. J Child Neurol 2011; 26:675.

Chitnis T, Tenembaum S, Banwell B, Krupp L, Pohl D, Rostasy K, et al.

Consensusstatement: evaluation of new and existing the rapeutics for pediatric multiple sclerosis. MultScler. 2012; 18:116-127.

Wassmer E, Chitnis T, Pohl D, Amato MP, Banwell B, Ghezzi A, et al. International Pediatric MS Study Group Global Members Symposium report. Neurology. 2016;30; 87: S110-116.

Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al; ITEMS (Immunomodulatory Treatment of Early-onset MS) Group. Long-termresults of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. NeurolSci. 2009;30(3):193-9.

Lattanzi S, Cagnetti C, Danni M,Provinciali L, Silvestrini M. Oral and intravenous steroidsfor multiple sclerosis relapse: a systematic reviewand meta-analysis. J Neurol 2017; 264:1697.

58. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Grant AR. Evidence-based guideline update: Plasmapheresis in neurologicdisorders: report of the Therapeutics and Technology Assessment Subcommittee of theAmerican Academy of Neurology. Neurology 2011; 76:294.

Fazekas F, Strasser-Fuchs S, Hommes OR. Intravenous immunoglobulin in MS: promise or failure? J Neurol Sci. 2007 Aug 15;259(1-2):61-6.

Chitnis T. Disease-modifyingtherapy of pediatric multiple sclerosis. Neurotherapeutics. 2013;10(1):89-96.

McGinley M.P, Goldschmidt C.H, Rae-Grant A.D. Diagnosis and treatment of multiple sclerosis: A review. Jama. 2021; 325: 765–779.

Jancic J, Nikolic B, Ivancevic N, Djuric V, Zaletel I, Stevanovic D, et al. Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options. Neurol. Ther. 2016; 5: 131–143.

Langille M.M, Rutatangwa A, Francisco C. Pediatric multiple sclerosis: A review. Adv. Pediatr. 2019; 66: 209–229. doi: 10.1016/j.yapd.2019.03.003.

An Q, Fan CH, Xu SM. Childhood multiple sclerosis: clinical features and recent developments on treatment choices and outcomes. Eur Rev Med Pharmacol Sci. 2018;22(17):5747-54.

Tenembaum SN, Banwell B, Pohl D, Krupp LB, Boyko A, Meinel M, et al. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospectivestudy. J Child Neurol. 2013;28(7):849– 56.

Krupp LB, Pohl D, Ghezzi A, Boyko A, Tenembaum S, Chen L, et al. Subcutaneous interferon beta-1a in pediatric patients with multiple sclerosis: Regional diferences in clinical features, disease management, and treatment outcomes in an international retrospective study. J NeurolSci. 2016; 363: 33–8.

Gartner J, Bruck W, Weddige A, Hummel H, Norenberg C, Bugge JP, et al. Interferon beta-1b in treatment-naivepaediatric patients with relapsing-remitting multiple sclerosis: Two-year results from the BETAPAEDIC study. MultScler J ExpTranslClin. 2017;3(4):2055217317747623.

Ghezzi A, Amato MP, Annovazzi P, Capobianco M, Gallo P, La Mantia L, et al. Long-termresults of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. NeurolSci. 2009;30(3):193–9.

Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003;34(3):120-6.

Nicotera AG, Spoto G, Saia MC, Midiri M, Turriziani L, Amore G, et al. Treatment of multiple sclerosis in children: A briefoverview. Clin Immunol. 2022; 237:108947.

Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–74.

Chitnis T, Tardieu M, Banwell B, Gücüyener K, Deiva K, Skripchenko N, et al. Evaluation of terifunomide in children and adolescents with relapsingms: Terikids phase 3 studydesign, Pediatric MS: Diagnosis, Prognosis and Treatment 59 enrollment update, and baseline data (P4.354). Neurology. 2018;90(15 Supplement): P4.354.

Chitnis T, Banwell B, Kappos L, Arnold DL, Gucuyener K, Deiva K, et al. Safetyandefcacy of terifunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlledtrial. Lancet Neurol. 2021;20(12):1001–11.

Ozel O, Vaughn CB, Eckert SP, Jakimovski D, Lizarraga AA, Weinstock-Guttman B. Dimethyl Fumarate in thetreatment of relapsing-remitting multiple sclerosis: patient reported out comes and perspectives. Patient Relat Outcome Meas. 2019;10: 373–84. Alroughani R, Das R, Penner N, Pultz J, Taylor C, Eraly S. Safety andefcacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple sclerosis (FOCUS). Pediatr Neurol. 2018; 83:19–24.

Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M, Blaschek A, Valis M, Aaen G, et al. Delayed-release dimethyl fumarate safety and efcacy in pediatric patients with relapsing-remitting multiple sclerosis. Front Neurol. 2020;11: 606418.

Ward MD, Jones DE, Goldman MD. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin Drug Saf. 2014;13(7):989-98.

Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Bruck W, et al. Temporal profle of lympho cytecounts and relationship with infections with fngolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Mult Scler. 2021;27(6):922–32.

Arnold DL, Banwell B, Bar-Or A, Ghezzi A, Greenberg BM, Waubant E, et al. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. J Neurol Neurosurg Psychiatry. 2020;91(5):483–92.

CinarBP, Konuskan B, Anlar B, Ozakbas S. Narrative review based on fingolimod therapy in pediatric MS. SAGE Open Med. 2023; 11: 20503121231171996.

Deiva K, Huppke P, Banwell B, Chitnis T, Gartner J, Krupp L, et al. Consistent control of disease activity with fngolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. J Neurol Neurosurg Psychiatry. 2020;91(1):58–66.

Yeh EA, Weinstock-Guttman B. Natalizumab in pediatric multiple sclerosis patients. Ther Adv Neurol Disord. 2010;3(5):293–9.

Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, et al. Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther. 2016;16(9):1151–62.

Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, et al. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurol Neuroimmunol Neuroinfamm. 2019;6(5): e591.

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, et al. Natalizumab in thepediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15:174.

Palavra F, Figueiroa S, Correia AS, Tapadinhas F, Cerqueira J, Guerreiro RP, et al. TyPedstudy: Natalizumab for the treatment of pediatric-onset multiple sclerosis in Portugal. Mult Scler Relat Disord. 2021;51: 102865.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J. Theuse of natalizumab in pediatric patients with active relapsing multiple sclerosis: a prospective study. Pediatr Neurol. 2017; 70:56–60.

Hauser SL, Bar-Or A, Comi G,Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376:221.

FDA approves new drug to treat multiple sclerosis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm (Accessed on March 30, 2017).

Ocrevus (ocrelizumab) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761053s029s030lbl.pdf (Accessed on August 05, 2022).

Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, et al. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy. JAMA Neurol 2021; 78:736.

Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Anneca R, et al. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis 2019; 6: ofy356.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon-beta-1a as frst-line treatment for patients with relapsing remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease modifying therapy: a randomised phase 3 trial. Lancet. 2012;380(9856):1829–CAMMS223 Trial Investigators. Alemtuzumab vs. interferon-beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359:1786–801.

European Medicines Agency. Lemtrada assessment report: procedure under article 20 of regulation (EC) No 726/2004 resulting from pharmaco vigilance data. 2019.

Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more efective than interferon b-1a at 5-year follow-up of CAMMS223 clinicaltrial. Neurology. 2012;78(14):1069–78.

Ziemssen T, Bass AD, Berkovich R, Comi G, Eichau S, Hobart J, et al. Efcacy and safety of alemtuzumab through 9 years of follow-up in patients with highlyactive disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs. 2020.

Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. MultScler. 2019;25(12):1605–17.

Syed YY. Alemtuzumab: a review in relapsing remitting multiple sclerosis. Drugs. 2021; 81: 157–68.

Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots R, Kim HJ, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 2019; 19:5.

Svenningsson A, Frisell T, Burman J,Salzer J,Fink K, Hallberg S, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol 2022; 21:693.

Hauser SL, Waubant E, Arnold DL, Vollmer T, Jack A, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676.

Salzer J, Svenningsson R, Alping P,Novakova L, Björck A, Fink K, et al. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. Neurology 2016; 87:2074.

Granqvist M, Boremalm M, Poorghobad A,Svenningsson A, Salzer J, Frisell T, et al. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis. JAMA Neurol 2018; 75:320.

Miller AE, Chitnis T, Cohen BA, Costello K,Sicotte NL, Stacom R, et al. Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 2021;78(2):241–6.

Burman J, Kirgizov K, Carlson K, Badoglio M, Mancardi GL, De Luca G, et al. Autologous hematopoietic stemcell transplantation for pediatric multiple sclerosis: a registry-basedstudy of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2017;52(8):1133

Hartung HP, Gonsette R,König N, Kwiecinski, Guseo A, Morrissey SP, et al. Mitoxantrone in prtogressive multiple sclerosis: a placebo-controlled double-blind, randomized, multicentertrial. Lancet. 2002;360(9350):2018–2025.

Edan G, Miller D, Clanet M,Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997; 62:112–118. doi: 10.1136/jnnp.62.2.112.

Vollmer T, Panitch H, Bar-Or A,Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. MultScler. 2008; 14:663–670.

Lefort M, Le Corre G, Le Page E,Rizzato C, Port DL, Michel L, et al. Ten-yearfollow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: an observational study of 100 consecutive patients. RevNeurol (Paris). 2022;178(6):569–579.

Le Page E, Leray E, Edan G, et al. Long-termsafety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. MultScler. 2011; 17:867–875.

Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Friedemann P, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012;5(2):75–79.

Okuda DT. Immunosuppressive treatments in multiple sclerosis. Handb Clin Neurol 2014; 122:503-11.

Ticha V, Kalincik T, Havrdova E. Interferon-β or azathioprine as add on therapies in patients with active multiple sclerosis. Neurol Res 2012; 34:923-30.

Patti F, Lo Fermo S. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis 2011; 2011:961702.

Chan ES, Cronstein BN. Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial. J Res Med Sci 2011;16: 457-62

Gray OM, McDonnell GV, Forbes RB. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006;12: 507-10.

Michel L, Vukusic S, De Seze J, et al. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients. J Neurol Neurosurg Psychiatry 2014;85: 279-83.

Xiao Y, Huang J, Luo H, Wang J. Mycophenolate mofetil for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev 2014:CD010242.

Tokuçoğlu F, Mirza M, Şen S, Uygunoğlu U. Multipl Sklerozda İmmünosüpresif Tedaviler ve IVIG. In, Multipl Skleroz Tanı ve Tedavi Kılavuzu 2018. Galenos Yayınevi, İstanbul, 2018, pp.108-121.